Mostrando 2 resultados de: 2
Filtros aplicados
Subtipo de publicación
Article(2)
Pulmonary Inflammatory Response in Lethal COVID-19 Reveals Potential Therapeutic Targets and Drugs in Phases III/IV Clinical Trials
ArticleAbstract: Background: It is imperative to identify drugs that allow treating symptoms of severe COVID-19. RespPalabras claves:clinical trials, drugs, lethal COVID-19, pulmonary inflammatory response, single nucleus RNA sequencingAutores:Alejandro Cabrera-Andrade, Álvaro A. Pérez-Meza, Ana María Gómez-Jaramillo, Andrea Abad-Sojos, Andrea V. Jácome, Andrés López-Cortés, Andy Pérez-Villa, Ángela León-Cáceres, Antonella Vera-Guapi, Ariana León-Sosa, Cevallos-Robalino D., Echeverría-Garcés G., Esteban Ortiz-Prado, Estefanía Abarca, Fernanda Arias-Erazo, Isaac Armendáriz-Castillo, Jennyfer M. García-Cárdenas, Jhommara Bautista, Katherine Simbaña-Rivera, Lourdes Puig San Andrés, Luis Fuenmayor-González, Morillo A., Nieto-Jaramillo K., Nikolaos C. Kyriakidis, P. Guevara-Ramírez, Quiñones L.A., Ramos-Medina M.J., Santiago Xavier Guerrero, Verónica YumicebaFuentes:scopusThe dynamics and determinants of specific systemic and mucosal antibody responses to SARS-CoV-2 in three adult cohorts in the Ecuadorian Andes: a study protocol
ArticleAbstract: Introduction: There are limited longitudinal data on the systemic and mucosal antibody responses toPalabras claves:Antibody levels, covid-19, ECUADOR, RISK FACTORS, SARS-COV-2, SeroprevalenceAutores:Fernanda Arias-Erazo, Jair Teran, Jose Leon-Rojas, Lizet Villacis, Miguel J. Martín, Monica Isabel Pérez, Natalia Cristina Romero, Patricia Jiménez, Philip John Cooper, Ricardo Recalde, Ster I.C., Tatiana Veloz, Velez J.Fuentes:googlescopus